MARCI GARCIA: Open Payments
NPI 1144097585 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,372 in 59 payments from 11 companies in 2025. Trend: 2023 $97 · 2024 $2,455 · 2025 $1,372
Food & beverage: $1,245Education: $127
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 13 | $496 |
| ABBVIE INC. | 16 | $181 |
| Neurocrine BioSciences, Inc. | 9 | $176 |
| Supernus Pharmaceuticals, Inc. | 3 | $139 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $110 |
| Alkermes, Inc. | 5 | $101 |
| E.R. Squibb & Sons, L.L.C. | 3 | $50 |
| Lundbeck LLC | 2 | $40 |
| GENZYME CORPORATION | 1 | $40 |
| Axsome Therapeutics, Inc. | 1 | $20 |
Products named: UZEDY, VRAYLAR, INGREZZA, Qelbree, CAPLYTA, COBENFY, AUSTEDO XR, VIVITROL.
Industry payments across TX — which companies pay providers there.
